1
University of Ljubljana-Faculty of Pharmacy, Ljubljana, Slovenia, 2 University of LjubljanaFaculty of Pharmacy, Ljubljana, SC, Slovenia OBJECTIVES: Studies have shown that the use of high-dose irinotecan in cancer therapy is associated with an increased risk for severe neutropenia in UGT1A1 7/7 genotype patients. The aim of the present study was to evaluate cost-effectiveness of UGT1A1 genotyping prior to administration of high-dose irinotecan in second-line colorectal cancer treatment. METHODS: UGT1A1 genotyping with subsequent initial irinotecan dose reduction or a prophylactic use of G-CSF in UGT1A1 7/7 genotype patients was compared to standard therapy in a decision analysis. The effectiveness outcome was severe neutropenia occurrence and number of life-years gained. Costeffectiveness of UGT1A1 genotyping was calculated separately for patients with African, Asian and Caucasian origin due to different UGT1A1 7/7 genotype frequencies. The analysis was performed from the USA health care payer perspective. RESULTS: UGT1A1 genotyping in combination with subsequent reduction of initial irinotecan dose for UGT1A1 7/7 genotype patients was cost-saving for the population of African and Caucasian origin. On the contrary, an incremental cost-effectiveness ratio was more than 6 mio USD per LYG for the population of Asian ancestry. Furthermore, UGT1A1 genotyping with subsequent prophylactic use of granulocytecolony stimulating factors in UGT1A1 7/7 genotype patients resulted in incremental cost-effectiveness ratio above 3 mio USD per life-year gained for all population groups. CONCLUSIONS: The use of UGT1A1 genotyping prior to high-dose irinotecan therapy could represent a good value for money for certain patient groups. : POTENTIAL CLINICAL AND  ECONOMIC IMPACT OF BIOMARKER DEVELOPMENT IN THE  DIAGNOSIS AND TREATMENT OF SINGLE PULMONARY NODULES  IN As part of a program using economic evaluation to guide discovery efforts in personalized medicine, we evaluated the potential clinical and economic impact of biomarker-directed management of patients with single pulmonary nodules (SPN) versus current practice in Luxembourg. METHODS: We developed a decision analytic model from the payer perspective using data from Luxembourg and neighboring countries. Decision pathways were based on input from clinical experts and health services researchers. The model follows patients from SPN identification to death comparing standard care (bronchoscopy, CT scans, and FDG PET scans) with biomarker-directed evaluation. Endpoints included lung cancers detected, false positive and negative tests, life expectancy, and related medical care costs. Threshold analyses were performed to assess levels of biomarker performance that would be cost-effective. RESULTS: Compared to standard care, biomarker-based management produced an average survival benefit of 0.015 years and average cost savings of a1430, dominating standard care. The improved life expectancy was primarily the result of identifying and treating patients with malignant tumors earlier. The cost savings were primarily driven by avoiding costly diagnostic procedures (e.g. FDG PET). In sensitivity analysis, test characteristics for bronchoscopy and FDG PET had the largest impact on model results. At a sensitivity/specificity of 0.83/0.83, the biomarker-based strategy was no longer more effective than standard care. There was no simultaneous decrease in sensitivity/specificity that made the biomarker based strategy more costly than standard care. Finally, the cost of the biomarker-based test could increase to a1530 with the strategy remaining less costly than standard care. CONCLUSIONS: Biomarkers have the potential to improve the management of patients diagnosed with SPN's in Luxembourg. At a sensitivity/specificity of 0.95/0.95, biomarker-directed management could improve outcomes and reduce costs for the Luxembourg health system. Biomarker development efforts at this and other strategic points along the lung cancer treatment pathway are underway. 4 Thomson Reuters, Hampden, ME, USA OBJECTIVES: Metastasectomy in patients with metastatic colorectal cancer (mCRC) is the best option to achieve long-term survival and offers the only chance for cure. Increasing the number of resectable patients is therefore a medical treatment goal. This study examines the trend over time in metastasectomy and pre-surgery chemo-and biologic therapy in newly diagnosed mCRC patients. METHODS: Using a large, U.S. medical claims database from a national commercially-insured population, we identified patients with newly diagnosed mCRC between 2001 and 2005. Metastasectomy rates by anatomic location were assessed for all mCRC patients during one year after mCRC diagnosis. Chemotherapy and/or biological therapy within 90 days prior to the date of metastasectomy was evaluated. RESULTS: A total of 1785 newly diagnosed mCRC patients were identified; of which 327 patients (18.3%) received metastasectomy within one year after mCRC diagnosis. This included 70 patients (3.9%) who were not initially resected but had metastasectomy following chemo-and/or biologic therapy. From 2001 to 2005, the most common surgery site was the liver (ranged 13.9%-16.7%), followed by the lung (2.3% to 4.9%) and pelvic resection (0.0%-0.5%). The percentage of patients who were not initially resected and had metastasectomy after receiving chemo-and/or biologic therapy increased from 2.9% in 2001 to 5.6% in 2005. Among patients who received pre-surgery chemo-and/or biologic therapy, the percentage of receiving biologic therapy increased rapidly in 2004-2005 from 35.0% to 77.3%. CONCLUSIONS: The proportion of patients with mCRC undergoing metastasectomy increased over time and the percentage of patients who were not initially resected and had metastasectomy after receiving chemo-and/or biologic therapy almost doubled during the study period.
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PCN159 TREND OF METASTASECTOMY AND CHEMO-AND BIOLOGIC THERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER
PCN160 MODELLING NUMBER OF CANCER PATIENTS POTENTIALLY TREATED WITH TARGETED PHARMACOTHERAPY IN THE CZECH REPUBLIC
Pavlik T 1 , Dusek L 1 , Majek O 1 , Koptikova J 1 , Vyzula R 2 , Finek J 3 1 Masaryk University, Brno, Czech Republic, 2 Masaryk Memorial Cancer Institute, Brno, Czech Republic, 3 University Hospital, Pilsen, Czech Republic OBJECTIVES: Modern targeted anticancer therapy introduces powerful treatment modality in cancer care. However, due to its cost the overall number of administrations has to be monitored and prospectively planned. The objective of this work is to design, apply and verify a multi-component statistical model that employs data from population records, clinical registries and data provided by an expert panel to predict the number of cancer patients who would be probably treated with targeted therapy in the following years. METHODS: Computations are primarily based on data from the Czech National Cancer Registry, which covers the entire population since 1977. The modelling process has two steps. In the first step, number of potentially treated cancer patients irrespective of drug is identified. The estimate combines the prediction of number of newly diagnosed and treated patients with the prediction of number of patients who were diagnosed previously and would probably be treated in a given year due to a relapse or progression of the primary malignant disease. In the second step patients are localised to individual drugs according to treatment scheme provided by the panel of experts, adjusted using information from clinical registries. RESULTS:
The model currently provides predictions of potentially treated patients with quantified uncertainties. Regarding the most common targeted anticancer therapies, following numbers of treated patients are estimated for 2009 (90% CI): 836 (725; 948) patients receiving trastuzumab for breast cancer, 1283 (859; 1705) patients receiving bevacizumab for colorectal cancer, 300 (151; 449) patients receiving cetuximab for colorectal cancer and 514 (469; 557) patients receiving erlotinib for non-small cell lung carcinoma. CONCLUSIONS: Presented model allows us to predict the number of patients requiring targeted anticancer therapy in the years to come. Final outcome is used by decision makers for planning of health care expenses in the Czech Republic.
PCN161 REIMBURSEMENT OF ADMINISTRATION COSTS ARE UNAFFECTED BY SINGLE, DOUBLE OR TRIPLE ANTI-CANCER THERAPY COMBINATIONS IN THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) IN FRANCE AND GERMANY
Rosery H 1 , Bischoff HG 2 , Vergnenegre A 3 , Chouaid C 4 , Walzer S 5 1 AiM GmbH Assessment-in-Medicine, Schopfheim, Germany, 2 Thoraxklinik Heidelberg, Heidelberg, Germany, 3 University Hospital, Limoges, France, 4 Hôpital Saint-Antoine, Paris, France, 5 F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland OBJECTIVES: The aim of this analysis is to compare the reimbursement rates for administration costs of triplet therapy bevacizumab-cisplatin-gemcitabine (BCG) versus doublet therapy cisplatin-pemetrexed (CP) for mNSCLC patients in France and German health care systems. METHODS: A systematic literature search performed in Medline, Embase, Cochrane, and Centre of Reviews and Dissemination databases identified 578 publications of anticancer agents. In addition, an evaluation of national reimbursement tariffs in both inpatient and outpatient settings was performed. Country-specific reimbursement structures were verified by two in-depth semi-structured expert oncologist interviews in each country. RESULTS: No publication including reimbursement tariffs for the administration of anticancer agents was identified during the systematic literature review. The evaluation of the national reimbursement tariffs showed significant costs for the administration service. The French GHS # 9606 "Chimiothérapie pour tumeur, en séances" is the reimbursement tariff of one inpatient chemotherapy session valued at a385.77 (public sector). The chemotherapy home infusion tariff code "chemotherapy, intravenous treatment" is valued at a374.16 irrespective of the number of injections administered. In Germany the inpatient reimbursement tariff G-DRG # E71B "Neubildung der Atmungsorgane" refers to the indication "neoplasm" with a cost of a1.671 for an inpatient visit and a610.40 for an outpatient visit. In both reimbursement systems these are flat rates irrespective of the number of chemotherapeutic drugs administered. CONCLUSIONS: When comparing the reimbursement for administrations of anticancer treatment combinations in France and Germany administration costs are unaffected by single, double or triple chemotherapy combinations. Therefore there is no difference in the cost of reimbursement for administration for BCG versus CP.
PCN162 REIMBURSEMENT OF ACTIVE-IMMUNOTHERAPEUTICS (AI): AN ANALYSIS BASED ON A STUDY OF CURENT REIMBURSEMENT APPROACHES
de Cambra S 1 , Mladsi D 2 , Neale S 3 , Faulkner EC 2 1 RTI Health Solutions, Barcelona, Spain, 2 RTI Health Solutions, Research Triangle Park, NC, USA, 3 RTI-Health Solutions, Otawa, Ontario, Canada OBJECTIVES: Despite implementation of radical cost control measures, pharmaceutical expenditure is expected to keep increasing due to highly innovative, expensive drugs, including immunotherapeutics. The objective of this study was to understand how different markets are responding to cost containment pressures, using a compareand-contrast approach of reimbursement decisions for three recently approved treatments for metastatic renal cell carcinoma (mRCC). Based on the findings we propose fundamentals to build acceptable reimbursement strategies for AI, including cancer vaccines. METHODS: We examined commonalities and differences of three drugs for mRCC, assessing drug costs, health technology assessments (HTA), and reimbursement decisions across 7 countries with similar pharmaceutical funding schemes (Canada, France, Germany, Italy, Spain, Sweden, and the UK). In each of the 7 countries primary reimbursement criteria for these drugs were identified, local HTAs were reviewed, and specific qualitative research with local payers and experts was conducted. For country comparisons, drug treatment costs were calculated from a payer perspective (6 weeks therapy). RESULTS: Treatment cost differences in the seven countries were minimal and mostly related to exchange rates indicating that, for innovative drugs, price convergence has been achieved in these countries. More than 70% of the total HTA evaluations conducted involved immunotherapeutics. Only the SMC assessment recommended against the use of the 3 studied drugs. Most countries apply or are studying some type of risk sharing scheme or access/restriction program for forthcoming drugs. CONCLUSIONS: Most payers accept high priced drugs; however, they certainly restrict patient access or set up different types of agreements with suppliers to be able to maintain budget control. Current reimbursement schemes in the countries studied will need to evolve according to similar parameters in order to give access to highly complex therapies as AI. In each country, the feasibility of implementing processes to track drug use, cost and outcomes will determine how these reimbursement schemes develop. A greater proportion of patients from large metros (17.4%) died in-hospital compared to small metros (7.0%), micropolitan (4.4%) and rural (5.2%) areas (p 0.001). Leading primary payer was Medicare for all four locations. Rural patients had the shortest mean length of stay (9.0 days). The mean length of stay differed significantly between rural (9.0 days) and micropolitan (10.0 days) patients. CONCLUSIONS: Colorectal cancer provides a significant burden to the health care system in West Virginia. Unlike previously reported in certain other states and countries, a greater proportion of urban residents in West Virginia are dying in-hospital due to CRC. The reasons for these disparities go beyond demographic differences between rural-urban residents and need to be explored.
PCN163 RURAL-URBAN DIFFERENCES IN COLORECTAL CANCER
PCN164 TWO DIFFERENT DOSES OF PALONOSETRON (PAL) FOR PREVENTION OF CHEMOTHERAPY-INDUCED VOMITING (CIV) IN PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC (MOHE) TREATMENT: SYSTEMATIC REVIEW (SR) AND META-ANALYSIS (MA)
Engel T 1 , Clark O 1 , Paladini L 1 , Faleiros E 1 , Clark LG 2 , Pegoretti B 1 1 Evidencias Medicas, Campinas, SP, Brazil, 2 Evidencias Medicas, Campinas, sp, Brazil OBJECTIVES: Chemotherapy-induced vomiting (CIV) is a frequent side effect of cancer treatment, with debilitating symptoms and negative effects on quality of life. CIV may be acute (within 24 hours of chemotherapy) or delayed (up to 7 days later). Different doses of PAL are available but the ideal one is still unknown. A recent metaanalysis demonstrated that PAL is more effective than other serotonin inhibitors in preventing nausea and CIV in patients receiving MoHE chemotherapy. We aimed to perform a SR and MA of all randomized controlled trials (RCT) comparing PAL 0.25 mg (or 0.3-1 mcg/kg) to PAL 0.75 mg (or 10 mcg/kg) as single intravenous doses in this setting of patients. METHODS: We searched several databases: MEDLINE, EMBASE, LILACS, and CENTRAL. The primary endpoints were the incidence of acute and delayed vomiting. The side effects of each treatment were analyzed. A subgroup analysis was planned and performed to evaluate the influence of the use of corticosteroids. The results of individual studies were pooled in MA, using the RevMan 5.1 software. The results are expressed as Risk Ratio (RR) and the correspondent 95% Confidence Interval (CI). RESULTS: Eight studies with 1674 patients were included. There was no difference between the efficacy of the evaluated doses in preventing either acute (RR 1.04; CI 95% 0.91 to 1.18; p 0.60) or delayed vomiting (RR 1.01; CI95% 0.90 to 1.13; p 0.89). There were no differences in side effects either: headache (RR 0.88; CI95% 0.64 to 1.20; p 0.41), dizziness (RR 1.20; CI95% 0.33 to 4.35; p 0.78), constipation (RR 0.67; CI95% 0.42 to 1.06; p 0.09) or diarrhea (RR 1.51; CI95% 0.43 to 5.31; p 0.52). The subgroup analysis found that the addition of corticosteroids had no impact on the efficacy of PAL. CONCLUSIONS: Both doses of PAL have equal efficacy and safety profile in preventing CIV in patients receiving MoHE chemotherapy. The choice of scheme, in this situation, must be the least costly one.
PCN165 SYSTEMATIC REVIEW OF PUBLISHED META-ANALYSES, SYSTEMATIC REVIEWS, AND HEALTH TECHNOLOGY ASSESSMENTS OF RITUXIMAB FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA
Santos EA, Minowa E Roche Brazil, Sao Paulo, SP, Brazil OBJECTIVES: To perform a review of the published meta-analyses, systematic reviews and health technology assessments reports (HTAR) which evaluated the use of rituximab for the treatment of non-Hodgkin lymphoma (NHL) regarding its benefits, safety profile and cost-effectiveness. METHODS: A search of MEDLINE, Lilacs, Cochrane library, Web of science and INAHTA websites from 1990 to 2009 was conducted. The following MESH terms were used: "Meta-Analysis", "Systematic Reviews", "Lymphoma, Non-Hodgkin", "Lymphoma, Large B-Cell, Diffuse" and "rituximab". Included studies were those which evaluated the use of rituximab alone and/or in combination with other therapies in first line, second line and maintenance therapy for naive, refractory patients or relapsed disease in different patient characteristics.
